We used thermostable group II intron reverse transcriptase sequencing (TGIRT-seq), which gives end-to-end sequence reads of highly structured RNAs, to identify >8,000 short (≤300 nt) full-length excised intron (FLEXI) RNAs in human cells. Most FLEXI RNAs are predicted to have stable secondary structures, making them difficult to detect by other RNA-seq methods. Some FLEXI RNAs correspond to annotated mirtron pre-miRNAs (introns that are processed into functional miRNAs) or agotrons (introns that bind AGO2 and function in a miRNA-like manner), but the vast majority had not been identified or characterized previously. FLEXI RNA profiles are cell-type specific, reflecting differences in host gene transcription, alternative splicing, or intron RNA turnover, and comparisons of matched tumor and healthy tissues from breast cancer patients and cell lines revealed hundreds of differences in FLEXI RNA expression. About half of the FLEXI RNAs contained one or more experimentally identified binding sites for a spliceosomal protein, AGO1-4, DICER, or a number of different regulatory proteins, suggesting multiple ways in which FLEXIs could contribute to the regulation of gene expression. As FLEXI RNAs are linked to the expression of thousands of protein-coding and lncRNA genes, they potentially constitute a new class of broadly applicable, highly discriminatory biomarkers for human diseases.